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Abstract In this study we evaluated the functionality and
inflammatory effects of P2Y14 receptors in murine N9
microglia. The selective P2Y14 receptor agonist UDP-
glucose (UDPG) derived from microbial sources dose
dependently stimulated expression of cyclooxygenase-2
and inducible nitric oxide synthase, and potentiated the
effects of bacterial lipopolysaccharide on nitric oxide
production. However, another selective P2Y14 receptor
agonist, UDP-galactose, did not affect these endpoints
either alone or in combination with lipopolysaccharide.
Interestingly, synthetic UDPG also had no detectable pro-
inflammatory effects, although P2Y14 receptors are both
expressed and functional in N9 microglia. While synthetic
UDPG decreased levels of phosphorylated cyclic AMP
response element binding protein, an effect that was
blocked by pertussis toxin, the pro-inflammatory effects
of microbial-derived UDPG were insensitive to pertussis
toxin. These data suggest that the pro-inflammatory effects
of microbial-derived UDPG are independent of P2Y14
receptors and imply that microbial-derived contaminants in
the UDPG preparation may be involved in the observed
inflammatory effects.
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Introduction
P2 purinergic receptors potently modulate microglial
inflammatory activities, but little is known concerning the
effects of P2Y14 receptors in these CNS-resident innate
immune cells. Previously, we and others have reported that
adenine di- and triphosphate nucleotides, the endogenous
ligands for P2 receptors, exert anti-inflammatory effects in
microglia [3, 4]; however, the specific P2 receptors
involved in these actions are not yet clear. The P2Y14
receptor, previously called GPR105 (an orphan G-protein
coupled receptor), has only recently been identified as a
member of the purinergic receptor family [1]; hence, com-
paratively little is known about its function in any cell type.
Its newly identified presence in microglia [5] suggests that
P2Y14 may have a role in modulating microglial responses
in the CNS. Uracil-containing sugar nucleotides, such as
uridine 5’ diphosphoglucose (UDPG) and UDP-galactose
(UDP-gal), are selective agonists for the P2Y14 receptor
[1], which couples intracellularly to the inhibition of
adenylyl cyclase via Gi/o [1, 8, 10, 11] in many cell types.
Adenylyl cyclase catalyzes the formation of cyclic AMP,
enabling protein kinase A (PKA) to phosphorylate and
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activate the transcription factor cAMP response element
binding protein (CREB), among many others. We under-
took the present studies to ascertain the role of P2Y14
receptors in modulating microglial cell inflammatory
functions.
Materials and methods
Materials The following materials were purchased from
Sigma Chemical (St. Louis, MO): LPS (E.coli 0111:B4),
ATP, UDP-glucose (microbial-derived; catalog #U4625,
multiple vials of lot #074K7024 over a period of 15 months)
and UDP-galactose (catalog #U4500). Synthetic UDP-
glucose was purchased from MP Biomedicals (Solon,
OH) and B. pertussis toxin (PTX) was obtained from
Calbiochem (San Diego, CA).
Cell culture Murine N9 microglia [9] were cultured
routinely in Dulbecco’s Modified Eagle’s Medium
(DMEM; Cellgro, Herndon, VA) supplemented with 5%
fetal bovine serum (Bio Whittaker, Walkersville, MD) and
100 U/ml penicillin/streptomycin (Cellgro) in 100-mm
Sarstedt plates. Cells were grown to ~90% confluency and
passaged every 2 days. For experimentation, cells were
plated at densities of 1×105 cells per well in 24-well plates
for nitrite measurements, or at 4×105 cells per well in 12-
well plates for signaling studies and RT-PCR. The next day,
the cells were treated as specified below.
Reverse-transcription polymerase chain reaction (RT-PCR)
RT-PCR was performed on 1 μg of total RNA from whole
brain (positive control) and N9 microglia as previously
reported [2, 4]. RT reactions were completed according to
the manufacturer’s protocol with and without reverse
transcriptase (+/-RT). The cDNA was then used for PCR
using the GoTaq Green Master Mix (Promega, Madison, WI).
The murine P2Y14 receptor gene was amplified using the
following primers: 5’TAGAGGCCATAAACTGTGC TT and
5’AATTCTTCCTGGACTTGAGGT (expected amplimer
size 742 bp). As a control, GAPDH (glyceraldehyde-
3-phosphate dehydrogenase; expected amplimer size
325 bp) was amplified using the following primers:
5’CCAT CACCATCTTCCAGGAG and 5’GATGGCATG
GACTGTGGTC. PCR products were separated and visu-
alized by ethidium bromide-stained 1% agarose gel
electrophoresis.
Measurement of nitrite production Cells were stimulated
with LPS (1 μg/mL) either alone or together with UDPG
for 18–22 h at the concentrations indicated. In some
experiments, cells were treated with increasing concentra-
tions of UDPG or UDP-gal alone (50–300 μM), or with
UDPG that had been boiled at 105°C for 30–60 min. In
other experiments, microglia were pretreated with PTX
(100 ng/mL) for 18 h, followed by stimulation with UDPG.
Nitric oxide (NO) levels were measured in the culture
medium using the Greiss reagent to analyze nitrite
production, a stable breakdown product of NO generation
[7]. The cells were collected for immunoblot analyses.
Immunoblot analyses Whole-cell lysates were prepared and
total protein content determined as previously described
[4]. Equal amounts of protein (~25 μg) were loaded per
lane and separated by 10% SDS-PAGE [6]. Proteins in the
gels were transferred to Immobilon polyvinylidene difluor-
ide (PVDF) membrane (Millipore, Bedford, MA), and the
membranes were subjected to immunoblot analyses for




































Fig. 1 UDPG potentiates LPS-stimulated NO release from N9
microglia. a Microglia were stimulated with vehicle (250 mM Hepes),
LPS (1 μg/ml), UDPG (150 and 300 μM), or LPS and UDPG together
for 18–22 h. Nitrite levels were determined using the Griess reagent.
The graph is representative of at least five independent experiments
performed in triplicate. b Microglia were treated with microbial-
derived UDPG at the indicated concentrations for 18–22 h and nitrite
levels assessed. **P<0.01, ***P<0.001
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[4]. To confirm equal protein loading, membranes were
probed with antibodies recognizing the cytosolic proteins
Grb-2 or GAPDH (Santa Cruz Biotechnology, Santa Cruz,
CA). The data shown are representative of at least three
independent experiments performed in triplicate.
Statistical analyses Statistical analyses were performed
using an ANOVA pre-hoc test and Tukey-Kramer, Dunnett
or Bonferroni multiple comparison post-hoc analyses.
Statistical significance was set at the 95% confidence limit
(P<0.05). Quantitative data are expressed as the mean ± SD
of three to six independent experiments.
Results
UDP-glucose stimulates nitric oxide (NO) production
in N9 microglia
To investigate the role of P2Y14-receptor activation in
microglia, we stimulated N9 cells with vehicle (Hepes
buffer), LPS (1 μg/mL), the P2Y14 agonist UDPG (150 or
300 μM), or combinations of both LPS and UDPG. LPS
strongly induced nitrite accumulation that was further
increased in the presence of UDPG (Fig. 1a), indicating
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Fig. 2 P2Y14 receptors are
expressed and functional in N9
microglia. a Total RNA was
isolated from two independently
cultured N9 microglial thaws
and from mouse whole brain as
a positive control. The reverse
transcription reaction was per-
formed with (+) or without (−)
reverse transcriptase (RT) fol-
lowed by PCR amplification of
P2Y14 mRNA (upper panel) or
GAPDH mRNA (lower panel)
as a control. b Microglia were
stimulated in triplicate for 5 or
15 min with vehicle (250 mM
Hepes), synthetic UDPG
(300 μM), or microbial-derived
UDPG (300 μM). Proteins from
triplicate treatments were pooled
and immunoblot analyses per-
formed for phosphorylated
CREB. Membranes were re-
probed for the presence of Grb-2
as a loading control. The figure
is representative of at least three
independent experiments each
performed in triplicate. c Quan-
tification of phosphorylated
CREB (pCREB) immunoreac-
tivity obtained from the densi-
tometric analyses of
immunoblot studies (n≥3) per-
formed as shown in b. Normal-
ized values (using Grb-2
immunoreactivity as a loading
control) are expressed as percent
CREB phosphorylation relative
to vehicle treatment, and the
data represent the mean ± SD of
at least three separate experi-
ments. **P<0.01 vs. vehicle
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and UDPG together. Maximum levels of UDPG-stimulated
nitrite accumulation occur between 100 and 300 μM UDPG
(Fig. 1b); therefore, 300 μM UDPG concentrations were
used in subsequent experiments. Because UDPG on its own
can robustly increase NO production, activation of P2Y14
receptors may be a pro-inflammatory signal for microglia.
P2Y14 receptors are functionally expressed in N9 microglia
To discern the specificity of the UDPG response, we
evaluated the expression of P2Y14 receptors in N9 micro-
glia by RT-PCR. Although not as great as in whole brain,
P2Y14 receptor mRNA was detectably expressed in N9
microglia (Fig. 2a). Because P2Y14 receptors couple to Gi,
we tested the ability of P2Y14-receptor ligands to decrease
CREB phosphorylation. As we have reported previously,
basal levels of phosphorylated CREB (pCREB) are rela-
tively high in microglia [4]. We therefore evaluated the
ability of synthetic UDPG (300 μM) and microbial-derived
UDPG (300 μM) to decrease CREB phosphorylation as an
indicator of their ability to functionally couple to the Gi/
adenylyl cyclase/cAMP/PKA pathway. Synthetic UDPG
decreased basal CREB phosphorylation levels at both 5 and
15 min, whereas microbial-derived UDPG did so only at
the earlier time point (Fig. 2b,c). Another P2Y14-receptor
agonist, UDP-gal (300 μM), also decreased CREB phos-
phorylation at both intervals (data not shown).
P2Y14 receptor-mediated reductions in CREB phos-
phorylation were evident at synthetic UDPG concentrations
between 10 and 50 μM, and they appeared to plateau
between 10 and 300 μM synthetic UDPG (Fig. 3a).
Importantly, these decreases in CREB phosphorylation
were prevented in the presence of PTX (Fig. 3b), suggest-
ing the involvement of P2Y14 receptors and Gi/o hetero-
trimeric G proteins in these effects.
Microbial-derived UDPG-stimulated NO production
is insensitive to pertussis toxin
To ascertain if the pro-inflammatory effects of microbial-
derived UDPG in N9 microglia were mediated by activa-
tion of P2Y14 receptors, we used PTX to prevent Gi/o
































































Fig. 3 Reductions in CREB phosphorylation stimulated by synthetic
UDPG are sensitive to PTX, whereas microbial-derived UDPG-
stimulated NO production is PTX insensitive. Quantification of
phosphorylated CREB immunoreactivity obtained from the densito-
metric analyses of immunoblot studies (n≥3). a Microglia were
stimulated in triplicate with synthetic UDPG at the concentrations
indicated for 15 min. b Microglia were pretreated with pertussis toxin
(PTX; 100 ng/mL) for 18 h prior to stimulation with synthetic UDPG
for 15 min. Proteins from triplicate treatments were pooled and
immunoblot analyses performed for phosphorylated CREB. Mem-
branes were re-probed for the presence of Grb-2 as a loading control.
Normalized numerical values (using Grb-2 immunoreactivity as a
loading control) are expressed as percent CREB phosphorylation
relative to vehicle treatment, and the data represent the mean ± SD of
at least three separate experiments. **P<0.01 and ***P<0.001 vs.
vehicle. c Microglia were pretreated in triplicate with vehicle (PBS) or
PTX (100 ng/mL) for 18 h prior to stimulation with either vehicle
(250 mM Hepes) or UDPG (300 μM) for 18–22 h. Nitrite levels were
determined using the Griess reagent. The graph represents cumulative
quantification of at least three independent experiments, wherein
treatments were performed in triplicate. ***P<0.001 vs. PTX alone

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shown in Fig. 3c, the presence of PTX did not interfere
with the ability of UDPG to stimulate nitrite accumulation,
suggesting a P2Y14 receptor-independent effect of micro-
bial-derived UDPG.
UDP-galactose is without effect on inflammatory gene
expression in N9 microglia
To further examine a role for P2Y14 receptors in promoting
the pro-inflammatory effects of microbial-derived UDPG,
we used another P2Y14 receptor agonist, UDP-gal. Unlike
in the case of UDPG, we did not observe any effect of
UDP-gal (75–300 μM) on either NO production (Fig. 4a)
or on the expression of inducible nitric oxide synthase
(iNOS) or cyclooxygenase-2 (COX-2; Fig. 4b). We have
used concentrations of UDP-gal as high as 5 mM and found
no detectable pro-inflammatory effects in our cell line (data
not shown). If P2Y14 receptors mediated the responses
to UDPG, then UDP-gal would be expected to act
similarly. Interestingly, boiled UDPG retained the ability
to dose dependently increase NO production (Fig. 4a),
supporting the idea that the UDPG contaminant is not heat
labile, consistent with the presence of microbial cell wall
products.
Synthetic UDP-glucose lacks pro-inflammatory activities
in N9 microglia
The microbial-derived UDPG that yielded the observed
pro-inflammatory effects in these studies was purchased
from a company that supplies the UDPG used in more than
90% of publications on P2Y14 receptors. Only a single lot
number (although multiple vials) of this UDPG (derived
from the microbial source Saccharomyces cerevisiae) was
available over the course of the 15-month duration of these
experiments. Because our data indicated that the pro-
inflammatory activity in the microbial-derived UDPG
preparation is independent of P2Y14 receptors, we pur-
chased a chemically synthesized UDPG preparation from a
different company (synthetic UDPG). As shown in Fig. 5,
synthetic UDPG was without effect on iNOS and COX-2
expression in N9 microglia, although it was capable of
reducing basal CREB phosphorylation levels (Fig. 3a).
Discussion
These studies indicate that UDPG preparations derived











Fig. 5 Microbial-derived UDPG stimulates iNOS and COX-2,
whereas synthetic UDPG does not. Microglia were stimulated in
triplicate for 18–22 h with either vehicle (250 mM Hepes), synthetic
UDPG (50, 150, or 300 μM) or microbial-derived UDPG (50, 150, or
300 μM). Proteins from triplicate treatments were pooled and
immunoblot analyses were performed for iNOS and COX-2 protein
levels. Membranes were re-probed for the presence of GAPDH as a
loading control. The figure is representative of at least three






















Fig. 4 The P2Y14-receptor ligand UDP-glucose, but not UDP-
galactose, is pro-inflammatory in N9 microglia. Microglia were
stimulated in triplicate with vehicle (V; 250 mM Hepes), UDPG (75,
150, or 300 μM), UDP-gal (75, 150, or 300 μM), or boiled UDPG
(75, 150, or 300 μM) for 18–22 h. a Nitrite levels in the medium were
determined using the Griess reagent. b Proteins were harvested,
pooled and analyzed by immunoblot analyses for iNOS (upper panel)
and COX-2 (middle panel). Grb-2 was used to control for protein
loading (lower panel). The data shown are representative of at least
three independent experiments
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ities that are independent of P2Y14 receptor activation. In
addition, our data suggest that selective activation of
P2Y14 receptors (by synthetic UDPG or by UDP-gal) has
no effect on the production of the inflammatory mediators
iNOS/NO and COX-2 by N9 microglia. Because synthetic
UDPG and UDP-gal inhibit the phosphorylation of CREB
in a manner that is sensitive to pertussis toxin, P2Y14
receptors appear to be expressed and functional in N9
microglia. However, because the pro-inflammatory effects
of microbial-derived UDPG on NO production were not
blocked by PTX, it is likely that these stimulatory effects in
microglia do not involve P2Y14 receptors.
Although the function of P2Y14 in any cell type remains
unclear, in immature dendritic cells, activation of P2Y14
receptors increases expression of CD86, suggesting their
involvement in dendritic cell maturation [13]. Also, pro-
inflammatory stimuli such as LPS [8] and interferon-γ
(JMC and JJW, unpublished observations) increase the
expression levels of GPR105 in glial cells and in N9
microglia, respectively, supporting the idea that this
receptor plays a role in the microglial response to pro-
inflammatory stimuli. While we did not observe any
modulatory effects of selective P2Y14 receptor activation
on iNOS or COX-2 pathways in microglia, it remains
probable that P2Y14 receptors alter some other microglial
inflammatory function(s) not measured here.
It is important to note that in addition to our study, other
literature reports also indicate different responses to UDPG
and UDP-gal. Whereas both UDPG and UDP-gal are
agonists of P2Y14 receptors [1, 14], in human neutrophils
[12] and in murine T-lymphocytes [10] UDP-gal does not
mimic the effects of UDPG. Coincidentally, the source of
UDPG used in the above studies was also microbial-
derived. In a separate set of studies, microbial-derived
UDPG had effects in a cell line in which P2Y14 receptors
were not detectably expressed [11], supporting the idea that
UDPG preparations from microbial sources may contain
some other activity that is independent of P2Y14 receptors.
Because many studies on P2Y14 receptor function are
performed in transfected cell systems, potential microbial
contaminants in the nucleotide preparations are admittedly
not as large a concern as when studies are performed in
immune cells, which can strongly respond to microbial
products. However, based on the data presented here, the
presence of microbial products in the nucleotide preparation
may significantly alter data interpretation.
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